Coronavirus disease 2019-associated coagulopathy

Giuseppe Lippi, Fabian Sanchis-Gomar, Emmanuel J Favaloro, Carl J Lavie, Brandon M Henry

Research output: Contribution to journalReview articlepeer-review

53 Citations (Scopus)

Abstract

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy, is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multiorgan dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mechanisms of COVID-19-associated coagulopathy and review the clinical, histopathologic, and laboratory evidence, which leads us to conclude that COVID-19 is both a pulmonary and vascular disorder.

Original languageEnglish
Pages (from-to)203-217
Number of pages15
JournalMayo Clinic Proceedings
Volume96
Issue number1
Early online date30 Oct 2020
DOIs
Publication statusPublished - Jan 2021

Fingerprint

Dive into the research topics of 'Coronavirus disease 2019-associated coagulopathy'. Together they form a unique fingerprint.

Cite this